<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2065">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134285</url>
  </required_header>
  <id_info>
    <org_study_id>81830045</org_study_id>
    <nct_id>NCT05134285</nct_id>
  </id_info>
  <brief_title>Effects of Recurrent PE on Women and Offspring</brief_title>
  <acronym>RPOH</acronym>
  <official_title>The Effects of Recurrent PE on Women and Offspring's Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dunjin Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the risk factors of recurrent preeclampsia and&#xD;
      compare the short-term and long-term adverse outcomes of women and their offspring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators collected women delivered twice in a row in our hospital. The investigators&#xD;
      divided these pregnant women into three groups. Women in the first group did not complicate&#xD;
      preeclampsia at both deliveries; Women in the second group complicated preeclampsia at the&#xD;
      first delivery or at the second delivery; women in the third group complicated preeclampsia&#xD;
      at two deliveries. The investigators explore the risk factors of recurrent preeclampsia and&#xD;
      measure blood pressure, blood lipids, thyroid function, glycosylated hemoglobin, ALT, AST, et&#xD;
      al. in one year, three years, and five years after the second delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>blood pressure and hypertension of women</measure>
    <time_frame>1year after the second deliver</time_frame>
    <description>blood pressure ≥140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure and hypertension of women</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>blood pressure ≥140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure and hypertension of women</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>blood pressure ≥140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure and hypertension of offspring</measure>
    <time_frame>1 year old</time_frame>
    <description>blood pressure≥140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure and hypertension of offspring</measure>
    <time_frame>3 years old</time_frame>
    <description>blood pressure≥140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure and hypertension of offspring</measure>
    <time_frame>5 years old</time_frame>
    <description>blood pressure≥140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of glycosylated hemoglobin in blood</measure>
    <time_frame>1 year after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of glycosylated hemoglobin in blood</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of glycosylated hemoglobin in blood</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of cholesterol, LDL, HDL, VLDL-C in blood</measure>
    <time_frame>1 year after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of cholesterol, LDL, HDL, VLDL-C in blood</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of cholesterol, LDL, HDL, VLDL-C in blood</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of FT3,FT4, and hTSH in blood</measure>
    <time_frame>1year after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of FT3,FT4, and hTSH in blood</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of FT3,FT4, and hTSH in blood</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of AST and ALT in blood</measure>
    <time_frame>1year after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of AST and ALT in blood</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of AST and ALT in blood</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI of offspring</measure>
    <time_frame>1 year old</time_frame>
    <description>weight(kg)/height(m)2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI of offspring</measure>
    <time_frame>3 years old</time_frame>
    <description>weight(kg)/height(m)2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI of offspring</measure>
    <time_frame>5 years old</time_frame>
    <description>weight(kg)/height(m)2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of insulin in blood</measure>
    <time_frame>1year after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of insulin in blood</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of insulin in blood</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of fructosamine in blood</measure>
    <time_frame>1year after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of fructosamine in blood</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of fructosamine in blood</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of AI37℃、AI4℃、PRA、ALD、AngII in blood</measure>
    <time_frame>1 year after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of AI37℃、AI4℃、PRA、ALD、AngII in blood</measure>
    <time_frame>3 years after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of AI37℃、AI4℃、PRA、ALD、AngII in blood</measure>
    <time_frame>5 years after the second deliver</time_frame>
    <description>women</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Recurrence</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>pregnancy without preeclampsia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preeclampsia</arm_group_label>
    <description>pregnancy complicated with preeclampsia at the first delivery or at the second delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>recurrent preeclampsia</arm_group_label>
    <description>pregnancy complicated with preeclampsia at two deliveries</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood pressure,BMI, blood sample</intervention_name>
    <description>Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>preeclampsia</arm_group_label>
    <arm_group_label>recurrent preeclampsia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        women with at least twice of delivery history are divided into three groups, control group&#xD;
        refers to women without preeclampsia history, the second group refers to women complicated&#xD;
        with preeclampsia at the first delivery or at the second delivery, the third group refers&#xD;
        to women complicated with preeclampsia at two deliveries.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women with at least twice of delivery history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women with chronic hypertension&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dunjin Chen</last_name>
    <phone>18928916722</phone>
    <email>gzdrchen@gzhmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510150</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dunjin Chen</last_name>
    </contact>
    <contact_backup>
      <last_name>Lili Du</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Dunjin Chen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

